Founded by ophthalmic innovator Sean Ianchulev, MD MPH, Iantrek develops micro-interventional technologies for glaucoma surgery and advances bio-interventional treatment through the uveoscleral pathway. Its portfolio includes AlloFlo Uveo scleral allograft tissue, the AlloSert Uveo delivery instrument, and C-Rex, which combines canaloplasty and goniotomy in one motion. The company’s CREST study has followed more than 450 eyes across 16 locations for at least two years, with findings reported in peer-reviewed publications.